On the other hand, we previously demonstrated that HPV18+ cervical cancer cell lines (CALO, INBL, and HeLa) can respond differentially to treatment with low and high concentrations of IL-2, inducing or inhibiting their proliferation, respectively [12,13,27]. This evidence concerns the gene IL2 and cervical cancer.